Compounds > sb 203580
Page last updated: 2024-09-05

sb 203580 and su 9516

sb 203580 has been researched along with su 9516 in 2 studies

Compound Research Comparison

Studies
(sb 203580)		Trials
(sb 203580)		Recent Studies (post-2010)
(sb 203580)		Studies
(su 9516)		Trials
(su 9516)		Recent Studies (post-2010) (su 9516)
3,48941,13742019

Protein Interaction Comparison

ProteinTaxonomysb 203580 (IC50)su 9516 (IC50)
Chain A, Cell division protein kinase 2Homo sapiens (human)0.13
Chain A, Cell division protein kinase 2Homo sapiens (human)0.13
Chain A, Cell division protein kinase 2Homo sapiens (human)0.13
Chain A, Cell division protein kinase 2Homo sapiens (human)0.13
photoreceptor-specific nuclear receptorHomo sapiens (human)1.194
Cyclin-T1Homo sapiens (human)1.5
G2/mitotic-specific cyclin-B2Homo sapiens (human)0.022
Cyclin-dependent kinase 1Homo sapiens (human)0.0712
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)1.6
Platelet-derived growth factor receptor betaHomo sapiens (human)0.12
Cyclin-dependent kinase 4Homo sapiens (human)0.7333
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)0.12
G2/mitotic-specific cyclin-B1Homo sapiens (human)0.095
Interferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)5
Cyclin-A2Homo sapiens (human)0.027
G1/S-specific cyclin-D1Homo sapiens (human)1.7
G1/S-specific cyclin-E1Homo sapiens (human)0.0887
Cyclin-dependent kinase 2Homo sapiens (human)0.0657
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.1233
Glycogen synthase kinase-3 alphaHomo sapiens (human)0.35
Glycogen synthase kinase-3 betaHomo sapiens (human)0.35
Cyclin-dependent kinase 7Homo sapiens (human)0.905
Cyclin-dependent kinase 9Homo sapiens (human)1.5
Cyclin-HHomo sapiens (human)0.905
CDK-activating kinase assembly factor MAT1Homo sapiens (human)0.905
Cyclin-dependent-like kinase 5 Homo sapiens (human)0.0435
Cyclin-dependent kinase 5 activator 1Homo sapiens (human)0.022
G2/mitotic-specific cyclin-B3Homo sapiens (human)0.022

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M1
Augustin, M; Davies, SP; Gao, Y; Harvey, KJ; Kovelman, R; Patel, UA; Woodward, A1

Other Studies

2 other study(ies) available for sb 203580 and su 9516

ArticleYear
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-18, Volume: 104, Issue:51

    Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases

2007
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
    The Biochemical journal, 2013, Apr-15, Volume: 451, Issue:2

    Topics: Aurora Kinases; Cluster Analysis; Drug Design; Drug Discovery; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Intracellular Signaling Peptides and Proteins; MAP Kinase Kinase 4; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Recombinant Proteins; Reproducibility of Results; Signal Transduction; Small Molecule Libraries; Structure-Activity Relationship; Syk Kinase

2013